BeWhere Holdings Inc. Reports Second Quarter 2023 Results
Toronto, Ontario–(Newsfile Corp. – August 24, 2023) – BeWhere (TSXV: BEW) (OTCQB: BEWFF) (“BeWhere” or…
Month: August 2023
Ocumension Therapeutics Announces 2023 Interim Results
HONG KONG, Aug 24, 2023 – (ACN Newswire) – Ocumension Therapeutics (“Ocumension” or the “Company”,…
Pinal County Federal Credit Union Wins 2023 Tekkie Award in the Category of “Artificial Intelligence/Machine Learning”
PCFCU’s partnership with Agent IQ recognized for its measurable success, efficient AI automation and self-service…
Owners’ Experience with BEV Advanced Tech More Problematic Than with ICE Vehicles, J.D. Power Finds
Genesis Ranks Highest Overall for Tech Innovation for Third Consecutive Year; Hyundai Ranks Highest among…
First Trust Launches First Trust S&P 500 Diversified Free Cash Flow ETF
An index-tracking ETF that provides exposure to companies with high free cash flow yield WHEATON,…
Emplifi Wins “Influencer Marketing Innovation Award” in 2023 MarTech Breakthrough Awards Program
Prestigious International Annual Awards Program Recognizes Standout Marketing, Advertising, and Sales Technology Around the World…
dotData Announces dotData Ops: A Revolution in MLOps
dotData Ops democratizes enterprise AI and ML, empowering BI & Analytics professionals with streamlined data,…
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
– Board of Director appointments follow the Company’s recent launch and $200 million Series A…
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
– Board of Director appointments follow the Company’s recent launch and $200 million Series A…
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out…
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out…
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC….
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC….
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced…
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced…
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin…
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin…
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”)…
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”)…
Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections
Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot…